New drug trial targets Tough-to-Treat head and neck cancers
NCT ID NCT06857279
Summary
This study is testing an experimental drug called HLX43 for people with advanced head and neck cancer that has returned or spread. The main goals are to find a safe and effective dose, see if it shrinks tumors, and monitor side effects. About 167 participants will receive the drug at different doses to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA OF HEAD AND/OR NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.